Skip Navigation

Primary Location:

University of Minnesota Medical Center, Fairview

Blood and Marrow Transplant Program
420 Delaware Street, Southeast
MMC 803
Minneapolis, MN 55455
(612) 273-2800
(888) 601-0787
http://www.fairviewbmt.org/

Secondary Location:

University of Minnesota Children's Hosp.

2450 Riverside Avenue
Minneapolis, MN 55455 USA
www.uofmchildrenshospital.org

Number of Transplants Performed

This center has been performing allogeneic transplants since 1968 and has been an NMDP transplant center since May 1988.

Transplants Reported (From Jan. 2011 to Dec. 2012 as reported by the centers)       Unrelated or Related Donor Auto-
logous

(PBSC or marrow)
Total (by transplant type)
Marrow PBSC Cord
Blood
Unrelated Donor
- Adult
19 10 85 --- 114
Unrelated Donor
- Pediatric
34 0 76 --- 110
Related Donor
- Adult
8 62 0 --- 70
Related Donor
- Pediatric
24 1 5 --- 30
Autologous
- Adult
--- --- --- 181 181
Autologous
- Pediatric
--- --- --- 20 20
Total
(by cell source)
85 73 166 201 525

To find centers that perform cord blood transplants, use the Search Tool on this site.


Patient Survival Information for this Center

Masonic Cancer Center University of Minnesota


This center's actual 1-year survival results are similar to the expected rate for this center.

The survival information we have for this center includes ONLY:

  1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2009, 2010 and 2011, and
  2. Who had their transplant at a U.S. transplant center, and
  3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 414 patients.

The actual 1-year survival of these patients is 67.5%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 65.3% and 73.7%.

For help with understanding these statistics, please see Understanding Transplant Outcomes (PDF).


Transplant Results by Patient's Age, Disease Type and Stage

University of Minnesota Medical Center, Fairview - Related

Survival by Patient's Age, Disease Type and Stage after Related Donor Transplantation

This report is based on first allogeneic transplants performed between January 2009 and December 2011 using related donors. It only includes patients with known survival status at 1-year post-transplant. In some cases, patients may have been alive at last reported follow-up that was less than one year. Those patients have not been included in this report. The first number represents the number of patients alive at one year post transplant. The second number is a total number of transplanted patients in that particular group.


Diagnosis 0-9 Yrs 10-19 Yrs 20-29 Yrs 30-39 Yrs 40-49 Yrs 50-59 Yrs 60+ Yrs Overall
Acute lymphoblastic leukemia in first complete remission 1/1 3/3 0/1 0/1 4/4 0/1 -- 8/11
Acute lymphoblastic leukemia in second complete remission 3/4 -- 0/1 0/1 -- -- -- 3/6
Acute myelogenous leukemia in first complete remission 2/3 -- 1/1 2/2 1/2 5/6 5/8 16/22
Acute myelogenous leukemia in second complete remission -- -- -- 1/1 -- 1/1 2/3 4/5
Acute myelogenous leukemia in third or higher complete remission, relapse, or primary induction failure -- -- 0/1 0/2 0/1 1/8 1/5 2/17
Auto immune diseases and other non-malignant diseases 4/5 1/2 -- -- -- -- -- 5/7
Chronic lymphocytic leukemia and other chronic leukemia -- -- -- -- 1/2 2/3 -- 3/5
Chronic myelogenous leukemia in first chronic phase -- 1/1 1/1 -- -- -- -- 2/2
Chronic myelogenous leukemia in accelerated phase or second chronic phase -- -- -- 1/1 -- -- -- 1/1
Hodgkin lymphoma 1/1 -- 1/1 0/1 -- -- -- 2/3
Inherited abnormalities of erythrocyte differentiation or function 7/8 3/3 -- 1/2 -- -- -- 11/13
Inherited disorders of metabolism 4/5 1/1 -- -- -- -- -- 5/6
Multiple myeloma / Plasma cell disorder -- -- -- -- 2/2 4/4 -- 6/6
Myelodysplastic disorders - Refractory anemia, Refractory anemia with ringed sideroblast, Refractory cytopenia with multilineage dysplasia, Refractory cytopenia with multilineage dysplasia and ringed sideroblast -- -- -- -- 1/1 2/2 -- 3/3
Myelodysplastic disorders - Refractory Anemia with excess blasts (with 5-9% brasts (RAEB-1) and 10-19% blasts (RAEB-2)) -- -- -- -- -- 1/2 4/4 5/6
Myelodysplastic disorders - Other MDS -- -- -- -- 1/1 -- 0/1 1/2
Non-Hodgkin lymphoma 0/1 -- 1/1 1/1 3/3 6/8 1/1 12/15
Other acute leukemia -- -- 2/2 -- -- -- -- 2/2
Severe aplastic anemia -- 6/6 -- -- -- -- -- 6/6
Solid tumors / Other malignancies -- -- -- -- -- -- 0/1 0/1
Total 22/28 15/16 6/9 6/12 13/16 22/35 13/23 97/139

University of Minnesota Medical Center, Fairview - Unrelated

Survival by Patient's Age, Disease Type and Stage after Unrelated Donor Transplantation

This report is based on first allogeneic transplants performed between January 2009 and December 2011 using unrelated donors. It only includes patients with known survival status at 1-year post-transplant. In some cases, patients may have been alive at last reported follow-up that was less than one year. Those patients have not been included in this report. The first number represents the number of patients alive at one year post transplant. The second number is a total number of transplanted patients in that particular group.


Diagnosis 0-9 Yrs 10-19 Yrs 20-29 Yrs 30-39 Yrs 40-49 Yrs 50-59 Yrs 60+ Yrs Overall
Acute lymphoblastic leukemia in first complete remission 3/3 2/5 0/1 2/5 1/2 2/2 2/2 12/20
Acute lymphoblastic leukemia in second complete remission 3/3 5/9 -- -- 0/2 -- 0/1 8/15
Acute lymphoblastic leukemia in third or higher complete remission, relapse, or primary induction failure 3/4 -- 0/1 0/1 -- -- -- 3/6
Acute myelogenous leukemia in first complete remission 1/4 4/4 0/2 2/3 6/7 4/6 7/15 24/41
Acute myelogenous leukemia in second complete remission 1/2 2/3 2/2 1/1 1/1 1/1 2/3 10/13
Acute myelogenous leukemia in third or higher complete remission, relapse, or primary induction failure 0/2 0/2 -- -- -- 1/1 0/3 1/8
Auto immune diseases and other non-malignant diseases 3/5 1/1 1/1 -- -- -- -- 5/7
Chronic lymphocytic leukemia and other chronic leukemia -- -- -- -- -- 2/3 -- 2/3
Chronic myelogenous leukemia in first chronic phase -- -- -- 2/2 -- 0/1 -- 2/3
Chronic myelogenous leukemia in accelerated phase or second chronic phase -- -- -- -- -- 1/2 -- 1/2
Disorders of the immune system 5/6 0/1 -- -- -- -- -- 5/7
Histiocytic disorders 3/4 0/1 -- -- -- -- -- 3/5
Hodgkin lymphoma -- 1/1 3/3 2/2 -- -- -- 6/6
Inherited abnormalities of erythrocyte differentiation or function 12/14 5/8 5/5 -- -- -- -- 22/27
Inherited disorders of metabolism 18/27 5/5 1/1 0/1 -- -- -- 24/34
Multiple myeloma / Plasma cell disorder -- -- -- -- 0/2 1/1 -- 1/3
Myelodysplastic disorders - Refractory anemia, Refractory anemia with ringed sideroblast, Refractory cytopenia with multilineage dysplasia, Refractory cytopenia with multilineage dysplasia and ringed sideroblast 1/1 -- -- -- 1/1 -- 1/4 3/6
Myelodysplastic disorders - Refractory Anemia with excess blasts (with 5-9% brasts (RAEB-1) and 10-19% blasts (RAEB-2)) -- 0/2 -- -- 1/1 4/6 0/3 5/12
Myelodysplastic disorders - Other MDS -- 1/1 0/1 0/1 1/1 -- -- 2/4
Myeloproliferative syndromes 2/2 -- -- -- -- 1/2 0/3 3/7
Non-Hodgkin lymphoma 3/3 0/1 -- 0/1 5/5 2/2 1/1 11/13
Other acute leukemia -- 0/1 -- -- -- 0/1 -- 0/2
Severe aplastic anemia 2/2 2/2 1/1 -- -- -- 0/1 5/6
Total 60/82 28/47 13/18 9/17 16/22 19/28 13/36 158/250

Program Description:

Transplant is a time of great challenge and great hope. At University of Minnesota Medical Center and University of Minnesota Children's Hospital, our blood and marrow transplant team offers superior clinical treatment along with compassionate and personalized patient care. Our physicians provide autologous and allogeneic transplant options for malignant and non-malignant disease including many rare genetic conditions. We have extensive expertise with different stem cell sources and conditioning intensities tailored to the patient's disease risk and tolerance for intense therapy. This experience allows us to provide specialized treatment options for patients including those with high risk, relapsed, and refractory disease. To date, our physicians have performed over 6,000 BMTs and continue to transplant more patients with umbilical cord blood than any other center in the country.

Contact Information:

If you have transplant-related questions, please contact Kathy French, transplant center coordinator, at (612) 273-2800 or by e-mail at kfrench1@fairview.org.

Program Type:

Adult and Pediatric

Attending Physicians:

(Medical Doctors)

Adult -

Mukta Aurora, Veronika Bachanova, Nelli Bejanyan, Claudio Brunstein, Linda Burns, Sarah Cooley, Dan Kaufman, Aleksandr Lazaryan, Brian McClune, Phillip McGlave, Jeffrey Miller, Arne Slungaard, Celalettin Ustun, Greg Vercelotti, Ericka Warlick, Dan J. Weisdorf

Pediatric -

Bruce Blazar, Troy Lund, Margaret L. MacMillan, Weston Miller, Paul Orchard, Angela Smith, Heather Stefanski, Jakub Tolar, Michael Verneris, John Wagner

Transplants Performed:

Marrow/PBSC, single cord, and double cord

Cord blood transplants performed on:

Adult and pediatric

Find research trials at this center here:

ClinicalTrials.gov

Estimated Search & Transplant Costs

The costs for a transplant vary greatly from center to center and depend on factors such as health insurance, disease type and disease stage of the patient, as well as center-specific billing policies. Examples of costs in the search and transplant include:

  • The amount and geographic location of donors tested
  • Testing needed to confirm a match
  • Processing and collecting of tissue-typing samples
  • Donor workup testing needed
  • Getting the marrow, PBSC or cord blood unit for transplant

For the best understanding of costs of transplant and follow-up for a specific transplant center, contact the center's Financial Representative.

help Explain Transplant Costs at Different Centers

Resources for financial information

If you have questions about costs and financial services at this transplant center, you can contact the center's financial representative, Angela Woodard by e-mail at Awoodar1@fairview.org or by phone at (612) 273-6048.

Financial services at this center could include:

  • Health insurance information
  • Financial assistance
  • Patient-related resources

Additional Information

Further information about this center, including the number and type of transplants performed in each of the last three years, and the support groups offered, may be found in the BMT InfoNet Transplant Center Directory:
http://www.bmtinfonet.org/transplantcenters.

BMT InfoNet (Blood & Marrow Transplant Information Network) is a nonprofit organization that provides information and emotional support to transplant patients and their families.